The Labs Layer: How Telehealth Programs Order Tests, and What It Costs

The four pieces you are actually assembling

A lab result reaching a patient chart is the output of four separate arrangements, and vendors in this layer bundle different subsets of them, which is the single biggest source of confusion when you compare quotes. The ordering rail is the software that turns a clinical decision into a requisition a lab will honor. The ordering clinician is the licensed person whose name is on that requisition. The collection method is how the sample physically happens: a kit mailed to a kitchen table, a patient walking into a draw site, or a phlebotomist arriving at a door. And the result path is where the data lands, who reviews it, and how an out-of-range value reaches a human who can act on it.

Vendors sort into three shapes against those four pieces. Ordering aggregators and APIs sell the rail: a single integration in front of multiple labs, with the ordering clinician either bundled or brought by you. At-home kit platforms and white-label suppliers sell the collection method plus, often, the rail and the clinician with it, branded as yours. Mobile phlebotomy networks sell only the draw, and expect the order and the lab relationship to already exist. Read every quote by asking which of the four pieces it actually covers, because two vendors can describe themselves identically and leave you holding different halves of the problem.

Ask every labs vendor the same four questions in the same order: who writes the order, who collects the sample, which lab runs the assay, and who owns the abnormal result. A quote that answers fewer than four is not a quote for the whole layer.

What it costs, and why so few will tell you

The honest headline from our verification pass: this is the least price-transparent layer in the telehealth stack. Of the twenty-one vendors profiled on September 8, 2026, eighteen published no pricing signal at all. Two published dollar figures. Junction publishes a Launch tier at $300 a month for wearable connectivity, with lab testing itself sitting on a custom Enterprise plan that carries its claim of no upcharge on the tests themselves; Travalab publishes mobile draws from $75 per visit with the first twenty-five miles of travel included and no insurance billing. A third, SiPhox, publishes partner tiers by kit volume rather than by dollar, with co-branding starting at thirty kits, gray label at one hundred, and white label at five hundred or more. Several of the eighteen do describe structure without amounts, which is worth something: cash-pay or wholesale models stated plainly enough that you know what shape of invoice to expect, just not its size.

That silence is not evasion so much as architecture. Test menus are enormous, assay costs vary by an order of magnitude across a panel, and most of these vendors are quoting a bundle whose contents you have not chosen yet. It does mean your model has to be built from questions rather than from a price page. Ask for the per-panel cost of the specific tests your care line orders, not a platform fee; the platform fee is usually the small number. Ask whether the vendor marks up the assay or passes it through, and get the answer in writing, because that single distinction moves the per-patient number more than anything else in the layer. Ask what a redraw costs when a sample hemolyzes, and what a no-show costs on a mobile draw, since both are routine rather than exceptional. Then divide the whole thing by the patients who will actually test, not by your patient count, because testing cadence is where labs budgets go wrong.

• Per-panel assay cost for your specific care line's tests, marked up or passed through, in writing
• The platform or rail fee separately from the tests, so you can see which one you are optimizing
• Redraw, hemolysis, and no-show handling, and who absorbs each
• Whether the ordering clinician is included, and in which states
• Turnaround time commitments, and what happens to them at your volume

The three collection paths price differently, and fail differently

These are tradeoffs to model per care line rather than a ranking, and we have no comparative cost or completion data across them, so treat the shape as the point and get the numbers from the vendors you actually shortlist. Kits scale and brand well, and for the self-collected formats they push the sample-quality question onto the patient's kitchen table, so model a completion rate rather than a shipment count and ask any kit vendor what theirs looks like for a program shaped like yours. Kits are not automatically the cheap option either: an expensive specialty assay costs what it costs regardless of how the sample arrives. Draw sites suit anything needing a venous sample or a fasting protocol, at the price of a scheduling step, which is where funnels leak. Mobile draws remove that step and are priced accordingly, which tends to fit high-value programs and can eat the margin on a cheap one.

Most real programs end up mixing paths by care line rather than picking one, and the mixing is where the vendor-shape question from the first section bites: a kit platform that bundles the ordering clinician and a phlebotomy network that assumes you already have one cannot be swapped for each other, even though both look like collection vendors on a slide. Decide the path per care line first, then shop vendors that match the path, rather than the reverse.

The rename problem is really a diligence problem

This layer consolidated harder than any other in the stack between 2024 and 2026, and the renaming makes ordinary diligence unreliable: a reference from last year may describe a company that no longer exists under that name. Vital became Junction. Rupa Health went into Fullscript. Ash Wellness became Ash, and its legacy domain now resolves to a domain marketplace, so an old link is not a dead link, it is a wrong one. LetsGetChecked, Truepill, and Alto Pharmacy came together under Fuze Health. Everly Health Solutions folded into Everlywell's enterprise motion. Function, a major Quest partner, acquired Getlabs, and Labcorp's own site describes Labcorp as a Getlabs investor since 2022, so a draw network that once read as neutral now sits between the two lab giants' ecosystems. Note the precision there: a partnership is not ownership, and an investor is not a parent, which is exactly the distinction this section asks you to keep.

The practical consequence is that in this layer you verify ownership, not just claims. Ask who owns the vendor today, whether the lab relationships behind it survived the last transaction, and what happens to your contract if the parent redirects the brand. Our directory keeps a dated record of these events for exactly this reason, and re-verifies quarterly plus out of cycle on any acquisition or rename.

In a consolidating layer, a two-year-old recommendation is a lead, not a reference. Confirm the company still exists under that name, still owns the same lab relationships, and still answers the same four questions.

A note on where we sit, since every other guide has one

EmbedCare operates the clinical, pharmacy, storefront, retention, and compliance layers behind partner brands on flat product rates, with a self-serve Launch tier starting at $495/mo. Labs are not one of the layers we sell, and this page is not a soft pitch for one. We built the directory behind it because our own stack index described nine layers and could only point at eight, and we wrote this guide because the directory answered which vendors exist without answering how the layer works. If your program needs labs, you will be assembling this yourself or buying it from someone on that list, and the four questions at the top of this page are the ones we would ask in your seat.